4-[(2,3-dichlorophenyl)amino]-7-ethoxy-6-[4-(2-hydroxyethyl)piperazin-1-yl]quinoline-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[(2,3-dichlorophenyl)amino]-7-ethoxy-6-[4-(2-hydroxyethyl)piperazin-1-yl]quinoline-3-carboxamide
• 英文别名: 4-(2,3-dichloroanilino)-7-ethoxy-6-[4-(2-hydroxyethyl)piperazin-1-yl]quinoline-3-carboxamide
• 化学式: C₂₄H₂₇Cl₂N₅O₃
• 分子量: 504.416
• InChiKey: MIQDNGLZJOHMLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  在 NaHB(OAc)3 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 生成 4-[(2,3-dichlorophenyl)amino]-7-ethoxy-6-[4-(2-hydroxyethyl)piperazin-1-yl]quinoline-3-carboxamide
  参考文献：
  名称：

  3-Amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile

  摘要：

  The optimization of compounds from the 3-amido-4-anilinoquinolines series of CSF-1R kinase inhibitors is described. The series has excellent activity and kinase selectivity. Excellent physical properties and rodent PK profiles were achieved through the introduction of cyclic amines at the quinoline 6-position. Compounds with good activity in a mouse PD model measuring inhibition of pCSF-1R were identified. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.044

文献信息

• 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS
  申请人：Cook Donald

  公开号：US20090054411A1

  公开（公告）日：2009-02-26

  The invention relates to chemical compounds of formula IA or IB: or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

  该发明涉及化学式IA或IB的化合物：或其药学上可接受的盐，其具有CSF-1R激酶抑制活性，因此在抗癌活性和人或动物体的治疗方法中有用。该发明还涉及制造所述化学化合物的过程，包含它们的制药组合物以及它们在制造用于在温血动物（如人类）中产生抗癌效果的药物中的使用。
• WO2007/119046
  申请人：——

  公开号：——

  公开（公告）日：——
• 3-Amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile
  作者：David A. Scott、Kirsten J. Bell、Cheryl T. Campbell、Donald J. Cook、Les A. Dakin、David J. Del Valle、Lisa Drew、Thomas W. Gero、Maureen M. Hattersley、Charles A. Omer、Boris Tyurin、Xiaolan Zheng

  DOI：10.1016/j.bmcl.2008.12.044

  日期：2009.2

  The optimization of compounds from the 3-amido-4-anilinoquinolines series of CSF-1R kinase inhibitors is described. The series has excellent activity and kinase selectivity. Excellent physical properties and rodent PK profiles were achieved through the introduction of cyclic amines at the quinoline 6-position. Compounds with good activity in a mouse PD model measuring inhibition of pCSF-1R were identified. (C) 2008 Elsevier Ltd. All rights reserved.